A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
| 対象疾患 | Hepatocellular Carcinoma |
|---|---|
| 相 | 第2相 |
| スポンサー | David Hsieh |
| ステータス | 完了 |
| 参加者数 | 35 名 |
| 介入（薬剤） | Pembrolizumab, Bavituximab |
| 開始日 | 2018年4月26日 |
| 完了日 | 2023年4月21日 |
| 結果公開日 | 2024年7月17日 |
概要
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.
Overall Response Rate
| Pembro + Bavi | 9 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)